<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138849</url>
  </required_header>
  <id_info>
    <org_study_id>BBT877-IPF-003</org_study_id>
    <nct_id>NCT04138849</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 in Healthy Japanese Male</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of BBT-877 Following Single Doses in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bridge Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KCRN Research, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bridge Biotherapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will collect safety, pharmacokinetic, and pharmacodynamic data in Japanese male
      subjects in order to support development worldwide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to Day 14.</time_frame>
    <description>The number of AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics_AUC (the area under the curve)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>AUC of BBT-877</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics_Cmax (peak concentration)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>Cmax of BBT-877</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics_plasma LPA (Lysophosphatidic acid)</measure>
    <time_frame>Day 1 to Day 4</time_frame>
    <description>plasma LPA (18:2 and 20:4) concentrations over time and percent decrease from baseline LPA level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>BBT-877 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BBT-877 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BBT-877 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBT-877 single dose</intervention_name>
    <description>Oral capsule, single dose.</description>
    <arm_group_label>BBT-877 High Dose</arm_group_label>
    <arm_group_label>BBT-877 Low Dose</arm_group_label>
    <arm_group_label>BBT-877 Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo single dose</intervention_name>
    <description>Oral capsule, single dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed the informed consent form as described in Appendix 3 which includes compliance
             with the requirements and restrictions listed in the informed consent form (ICF) and
             in this protocol

          2. Healthy male 18 to 55 years of age inclusive at the time of signing the informed
             consent form

          3. Continuous non-smoker who has not used nicotine-containing products for at least 3
             months prior to dosing and throughout the study.

          4. Overtly healthy as determined by medical evaluation including medical history,
             physical examination, clinical laboratory tests

          5. Body mass index (BMI) within 18 to 30.0 kg/m2 (inclusive) and body weight not less
             than 50 kg

          6. Blood pressure (after supine for 5 minutes) between 90 and 140 mmHg systolic,
             inclusive, and no higher than 90 mmHg diastolic.

          7. A 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and
             function.

          8. Must agree to use contraception as detailed in Appendix 5 of this protocol during the
             treatment period and for at least 90 days after dosing of study treatment and refrain
             from donating sperm during this period

          9. Be first generation Japanese.

        Exclusion Criteria:

          1. Has a history of or current clinically significant medical illness that the
             investigator considers should exclude the subject or that could interfere with the
             interpretation of the study results.

          2. Clinically significant abnormal values for hematology, clinical chemistry, or
             urinalysis at screening and Day -1 as deemed appropriate by the investigator

          3. Clinically significant abnormal physical examination, vital signs or 12 lead ECG at
             screening and Day -1 as deemed appropriate by the investigator

          4. Has donated blood or had a significant blood loss (â‰¤500 mL) within 8 weeks of Day 1 or
             history of anemia or history of decreased red blood cells (RBC).

          5. Donated plasma within 7 days of Day -1

          6. Estimated creatinine clearance &lt;80 mL/min

          7. Liver function tests (serum alkaline phosphatase [ALP], aspartate transaminase [AST],
             alanine aminotransferase [ALT]) and serum bilirubin (total and direct) 1.2 times above
             the upper limit of normal (ULN) at Screening or Day -1.

          8. Baseline hemoglobin, hematocrit, red blood cell count below the lower limit of normal
             at Screening and Day -1.

          9. Has a history of human immunodeficiency virus (HIV) antibody positive, or tests
             positive for HIV; has a history of hepatitis B surface antigen (HBsAg) or hepatitis C
             antibody (anti-HCV) positive, or other clinically active liver disease, or tests
             positive for HBsAg or anti-HCV at Screening.

         10. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of
             Mental Disorders (4th edition) criteria within 5 years before screening or positive
             test result(s) for alcohol and/or drugs of abuse at screening and Day -1.

         11. Positive cotinine test at Screening and Day -1.

         12. History of presence of hypersensitivity or idiosyncratic reaction to the study drug(s)
             or related compounds.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Hyun Ryou, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bridge Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

